HK1046272A1 - 制备[S-(R*，S*)]-β-[[[1-[1-氧代-3-(4-(哌啶基)丙基]-3-哌啶基]羰基]氨基]-3-吡啶丙酸及其衍生物的方法 - Google Patents

制备[S-(R*，S*)]-β-[[[1-[1-氧代-3-(4-(哌啶基)丙基]-3-哌啶基]羰基]氨基]-3-吡啶丙酸及其衍生物的方法 Download PDF

Info

Publication number
HK1046272A1
HK1046272A1 HK02107463.1A HK02107463A HK1046272A1 HK 1046272 A1 HK1046272 A1 HK 1046272A1 HK 02107463 A HK02107463 A HK 02107463A HK 1046272 A1 HK1046272 A1 HK 1046272A1
Authority
HK
Hong Kong
Prior art keywords
formula
compound
salt
hydrogen
lower alkyl
Prior art date
Application number
HK02107463.1A
Other languages
English (en)
Chinese (zh)
Inventor
H. Cohen Judith
Justus Michael
A. Maryanoff Cynthia
Rossler Armin
Harmen Schroder Fridtjof
L. Sorgi Kirk
John Villani Frank Jr.
Weh Christian
Original Assignee
奥索-麦克尼尔药品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奥索-麦克尼尔药品公司 filed Critical 奥索-麦克尼尔药品公司
Publication of HK1046272A1 publication Critical patent/HK1046272A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02107463.1A 1999-03-22 2000-03-21 制备[S-(R*，S*)]-β-[[[1-[1-氧代-3-(4-(哌啶基)丙基]-3-哌啶基]羰基]氨基]-3-吡啶丙酸及其衍生物的方法 HK1046272A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12567199P 1999-03-22 1999-03-22
US60/125,671 1999-03-22
PCT/US2000/007462 WO2000056730A1 (en) 1999-03-22 2000-03-21 PROCESS FOR PREPARING [S-(R*,S*)] -β -[[[1-[1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES

Publications (1)

Publication Number Publication Date
HK1046272A1 true HK1046272A1 (zh) 2003-01-03

Family

ID=22420863

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107463.1A HK1046272A1 (zh) 1999-03-22 2000-03-21 制备[S-(R*，S*)]-β-[[[1-[1-氧代-3-(4-(哌啶基)丙基]-3-哌啶基]羰基]氨基]-3-吡啶丙酸及其衍生物的方法

Country Status (22)

Country Link
US (2) US6515130B1 (enExample)
EP (1) EP1165543B1 (enExample)
JP (1) JP2002540108A (enExample)
KR (1) KR20020019895A (enExample)
CN (1) CN1351600A (enExample)
AT (1) ATE242235T1 (enExample)
AU (1) AU775413B2 (enExample)
BR (1) BR0010652A (enExample)
CA (1) CA2368024A1 (enExample)
CZ (1) CZ20013431A3 (enExample)
DE (1) DE60003169T2 (enExample)
DK (1) DK1165543T3 (enExample)
ES (1) ES2199805T3 (enExample)
HK (1) HK1046272A1 (enExample)
HR (1) HRP20010767A2 (enExample)
HU (1) HUP0201262A3 (enExample)
MX (1) MXPA01009615A (enExample)
PT (1) PT1165543E (enExample)
SK (1) SK13562001A3 (enExample)
UA (1) UA67832C2 (enExample)
WO (1) WO2000056730A1 (enExample)
YU (1) YU74601A (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367971A1 (en) 1999-03-22 2000-09-28 Ortho-Mcneil Pharmaceutical, Inc. Synthesis of 3-amino-3-aryl propanoates
BR0212896A (pt) * 2001-09-21 2004-10-13 Sanofi Synthelabo Derivados de 2-piridinil-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4- ona e 7-piridinil-2,3dihidroimidazo[1,2-a] pirimidin-5(1h)ona substituìdos
HRP20170464T1 (hr) 2011-08-17 2017-05-19 Piramal Imaging Sa Spojevi za vezanje na glikoprotein iib/iiia specifičan za trombocite i njihova upotreba u vizualiziranju ugrušaka
EP2956461A1 (en) 2013-02-12 2015-12-23 Bayer Pharma Aktiengesellschaft Metal chelate compounds for binding to the platelet specific glycoprotein iib/iiia
EP2958894B8 (en) 2013-02-20 2020-02-26 Reuter Chemische Apparatenbau e.K. Process for the preparation of enantiomerically enriched 3-aminopiperidine
US20160068486A1 (en) 2013-04-22 2016-03-10 Reuter Chemische Apparatebau Kg Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58243B1 (en) 1983-12-07 1993-08-11 Lonza Ag A process for the preparation of optically-active 3-amino carboxylic acids
US5254573A (en) 1991-10-15 1993-10-19 Monsanto Company Substituted heterocyclic derivatives useful as platelet aggregation inhibitors
DE69429328T2 (de) 1993-09-22 2002-06-13 Fujisawa Pharmaceutical Co., Ltd. N-(3-piperidinylcarbonyl)-b-alanin derivate als paf-antagonisten
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
KR19990087694A (ko) * 1996-03-13 1999-12-27 후지야마 아키라 피브리노겐 수용체 길항제로서의 N-[(R)-１-{３-(４-피페리딜)프로피오닐-３-피페리딜카보닐]-２(S)-아세틸아미노-β-알라닌
ES2320316T3 (es) * 1996-05-01 2009-05-21 Ortho-Mcneil Pharmaceutical, Inc. Derivados carboxamida de pirrolidina, piperidina y hexahidroazepina utiles en el tratamiento de trastornos tromboticos.
US5840961A (en) 1996-07-12 1998-11-24 G. D. Searle & Co. Asymmetric synthesis of chiral beta-amiNo acids
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders

Also Published As

Publication number Publication date
ATE242235T1 (de) 2003-06-15
EP1165543A1 (en) 2002-01-02
CN1351600A (zh) 2002-05-29
CZ20013431A3 (cs) 2003-04-16
UA67832C2 (uk) 2004-07-15
SK13562001A3 (sk) 2002-08-06
AU775413B2 (en) 2004-07-29
ES2199805T3 (es) 2004-03-01
HUP0201262A2 (en) 2002-08-28
US6515130B1 (en) 2003-02-04
MXPA01009615A (es) 2003-07-21
KR20020019895A (ko) 2002-03-13
YU74601A (sh) 2004-05-12
AU3766100A (en) 2000-10-09
US20020137937A1 (en) 2002-09-26
BR0010652A (pt) 2002-07-16
EP1165543B1 (en) 2003-06-04
DK1165543T3 (da) 2003-09-29
HUP0201262A3 (en) 2003-12-29
DE60003169T2 (de) 2005-10-27
PT1165543E (pt) 2003-10-31
HU0201262D0 (enExample) 2002-05-29
DE60003169D1 (de) 2003-07-10
WO2000056730A1 (en) 2000-09-28
HRP20010767A2 (en) 2002-12-31
JP2002540108A (ja) 2002-11-26
CA2368024A1 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
US8741927B2 (en) Production method of intermediate compound for synthesizing medicament
CN1135209A (zh) 新的氨基甲酸苯基烷基氨基醇酯及其制备方法
EA008192B1 (ru) Способ получения (s,s)-цис-2-бензгидрил-3-бензиламинохинуклидина
WO2024092892A1 (zh) 依度沙班中间体及其制备方法
CN1301963C (zh) 制备n－(4－氟苯基)－n－(2－羧基－4－氯苯基)甘氨酸的方法
CN1351600A (zh) 制备[S－(R*,S*)]－β－[[[1－[1－氧代－3－(4－(哌啶基)丙基]－3－哌啶基]羰基]氨基]－3－吡啶丙酸及其衍生物的方法
TWI386395B (zh) 哌啶衍生物的立體有擇合成
JP3699769B2 (ja) ペプチド型化合物
CN1105098C (zh) Nmda拮抗剂的制备方法
US20110065930A1 (en) Process for the synthesis of (2s,3ar,7as)-octahydro-1h-indole carboxylic acid as an intermediate for trandolapril
CN1358170A (zh) (一)－(1s,4r)n－保护4－氨基－2－环戊烯－1－羧酸酯的制备方法
EP2736875A1 (en) Chemical process for opening ring compounds
JP2002316977A (ja) 光学活性１ｈ−３−アミノピロリジン化合物の製造方法
EP1699764A1 (en) Bis-dicarboxylic acid salts of benazepril and preparation of benazepril via these salts
HK1184787B (en) Production method of intermediate compound for synthesizing medicament